Connect with us

Business Wire

Navidea Biopharmaceuticals Prices $6.0 Million Public Offering of Common Stock

Business Wire

Published

on

Reading Time: 4 minutes

DUBLIN, Ohio–(BUSINESS WIRE)–Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the
“Company”), a company focused on the development of precision
immunodiagnostic agents and immunotherapeutics, today announced the
pricing of its previously announced underwritten public offering of
8,000,000 shares of common stock at a price to the public of $0.75 per
share. Navidea has also granted the underwriter a 30-day option to
purchase up to an additional 1,200,000 shares of common stock at the
public offering price, less underwriting discounts and commissions. The
offering is expected to close on or about June 18, 2019, subject to
customary closing conditions.

H.C. Wainwright & Co. is acting as sole underwriter for the offering.

The gross proceeds of the offering are expected to be $6.0 million (or
$6.9 million if the underwriter exercises in full its option to purchase
additional shares of common stock), prior to deducting underwriting
discounts and commissions and other estimated offering expenses. Navidea
intends to use the net proceeds from the offering to fund its research
and development programs, including continuing to advance its Phase 2b
and Phase 3 clinical trials of Tc99m tilmanocept in patients with
rheumatoid arthritis, and for general working capital purposes and other
operating expenses.

A registration statement on Form S-3 was filed by Navidea with the U.S.
Securities and Exchange Commission (“SEC”) and was declared effective by
the SEC on December 27, 2017. A preliminary prospectus supplement and an
accompanying prospectus relating to and describing the terms of the
offering and the shares of common stock being offered was filed with the
SEC on June 13, 2019, and is available on the SEC’s website at http://www.sec.gov.
Copies of the final prospectus supplement and the accompanying
prospectus relating to the offering may be obtained, when available,
from H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York,
NY 10022, or by calling (646) 975-6996 or by emailing placements@hcwco.com,
or at the SEC’s website at
http://www.sec.gov.

This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities of the Company, nor shall
there be any sale of Navidea’s common stock in any state or other
jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities
laws of any such state or jurisdiction.

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is developing
multiple precision-targeted products based on its Manocept™ platform to
enhance patient care by identifying the sites and pathways of disease
and enable better diagnostic accuracy, clinical decision-making, and
targeted treatment. Navidea’s Manocept platform is predicated on the
ability to specifically target the CD206 mannose receptor expressed on
activated macrophages. The Manocept platform serves as the molecular
backbone of Tc99m tilmanocept, the first product developed and
commercialized by Navidea based on the platform. The development
activities of the Manocept immunotherapeutic platform are being
conducted by Navidea in conjunction with its subsidiary, Macrophage
Therapeutics, Inc. Navidea’s strategy is to deliver superior growth and
shareholder return by bringing to market novel products and advancing
the Company’s pipeline through global partnering and commercialization
efforts.

For more information, please visit www.navidea.com.

Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. We have
based these forward-looking statements largely on our current
expectations and projections about future events and financial trends
affecting the financial condition of our business. Forward looking
statements include our expectations for the use of proceeds received
from the offering. These forward-looking statements are subject to a
number of risks, uncertainties and assumptions, including, among other
things: market and other conditions, the satisfaction of customary
closing conditions related to the public offering and the impact of
general economic, industry or political conditions in the United States
or internationally, any future actions by Platinum-Montaur; general
economic and business conditions, both nationally and in our markets;
our history of losses and uncertainty of future profitability; the final
outcome of any pending litigation; our ability to successfully complete
research and further development of our drug candidates; the timing,
cost and uncertainty of obtaining regulatory approvals of our drug
candidates; our ability to successfully commercialize our drug
candidates; our expectations and estimates concerning future financial
performance, financing plans and the impact of competition; our ability
to raise capital sufficient to fund our development and
commercialization programs; our ability to implement our growth
strategy; anticipated trends in our business; advances in technologies;
our ability to comply with the NYSE American continued listing
standards; our ability to maintain effective internal control over
financial reporting; and other risk factors detailed in our most recent
Annual Report on Form 10-K and other SEC filings. You are urged to
carefully review and consider the disclosures found in our SEC filings,
which are available at http://www.sec.gov or
at http://ir.navidea.com.

Investors are urged to consider statements that include the words
“will,” “may,” “could,” “should,” “plan,” “continue,” “designed,”
“goal,” “forecast,” “future,” “believe,” “intend,” “expect,”
“anticipate,” “estimate,” “project,” and similar expressions, as well as
the negatives of those words or other comparable words, to be uncertain
forward-looking statements.

You are cautioned not to place undue reliance on any forward-looking
statements, any of which could turn out to be incorrect. We undertake no
obligation to update publicly or revise any forward-looking statements,
whether as a result of new information, future events or otherwise after
the date of this report. In light of these risks and uncertainties, the
forward-looking events and circumstances discussed in this report may
not occur and actual results could differ materially from those
anticipated or implied in the forward-looking statements.

Contacts

Navidea Biopharmaceuticals, Inc.
Jed Latkin, CEO, 614-973-7490
jlatkin@navidea.com

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

For the last half century, thousands of communications professionals have turned to us to deliver their news to the audiences most important to their business through the sources they trust most. Over that time, we've gone from a single office with one full time employee to more than 500 employees in 32 bureaus.

Business Wire

Motorola Solutions to Showcase the Latest in Mission-Critical Innovation at CCW 2019

Business Wire

Published

on

Reading Time: 2 minutes

Enabling public safety and enterprise organisations to rise to the
challenge with a complete, integrated mission-critical ecosystem

KUALA LUMPUR, Malaysia–(BUSINESS WIRE)–Motorola
Solutions
will demonstrate how its advanced, mission-critical
solutions enable public safety and enterprise organisations to overcome
their most complex challenges at Critical
Communications World 2019
(June 18-20, MITEC, Kuala Lumpur,
Malaysia, booth G30).

At CCW 2019, Motorola Solutions will showcase a comprehensive set of
innovations spanning mission-critical communications, command centre
software, video security solutions and managed and support services.

Mission-critical communications are essential to maintaining safety and
security for our communities, from daily operations to extreme events
including disaster recovery. These solutions are essential for the Asia
Pacific region, as evidenced by a United Nations report estimating that
economic losses from natural disasters could reach USD$160
billion annually by 2030
. Organisations also demand new solutions to
augment voice communication with the unprecedented volumes of data and
video available today.

To address this need, Motorola Solutions has brought together a
comprehensive, integrated mission-critical ecosystem of technologies
comprising:

  • Mission-Critical Communications: including the TLK100
    and LEX
    L11 LTE
    devices that show what is possible over LTE networks and
    the ultra-portable LXN505
    public safety LTE infrastructure system.
  • Command Centre Software: to streamline and simplify daily
    workflows including CommandCentral
    Aware
    , the world’s only unified, proven, end-to-end public safety
    applications suite.
  • Video Security Solutions: including the latest from Avigilon’s
    video security and analytics portfolio including the H4
    Thermal camera
    with self-learning video analytics.
  • Managed & Support Services: to enable customers to focus on
    their mission while staying ahead of cybersecurity threats.

Having access to the right data enables organisations to make fast and
accurate decisions about where to place their valuable resources, which
work to prioritise and how to prepare for their most challenging
events,” Motorola Solutions corporate vice president, Mike deVente, said.

The mission-critical ecosystem we are demonstrating at CCW draws on our
90 year heritage of innovation and our strong understanding of
customers’ daily operational needs,” he said.

At CCW, commercial customers in the transportation, energy and utilities
segments will also learn how Motorola Solutions’ mission-critical
ecosystem and the innovations in critical communications can be
customised to meet their needs. One recent example of this is Motorola
Solutions’ successful integration work with Siemens to achieve railway
signalling over TETRA networks to European Train Control System (ETCS)
Level 2 standards.

About Motorola Solutions

Motorola Solutions is a global leader in mission-critical
communications. Our technology platforms in communications, command
center software, video security solutions and managed and support
services make cities safer and help communities and businesses thrive.
At Motorola Solutions, we are ushering in a new era in public safety and
security. Learn more at http://www.motorolasolutions.com.

MOTOROLA, MOTOROLA SOLUTIONS and the Stylized M Logo are trademarks
or registered trademarks of Motorola Trademark Holdings, LLC and are
used under license. All other trademarks are the property of their
respective owners. ©2019 Motorola Solutions, Inc. All rights reserved.

Contacts

Media Contacts
Damien Batey
Motorola Solutions
Mobile: +61
(0) 428 036 806
Damien.Batey@motorolasolutions.com

Michael
Lee
Motorola Solutions
Mobile: +65 9755 7025
MichaelKitWai.Lee@motorolasolutions.com

Continue Reading

Business Wire

Motorola Solutions celebrates 45 years of global innovation in Malaysia

Business Wire

Published

on

Reading Time: 2 minutes

Mission-critical ecosystem of technologies developed in Penang, taken
to the world

PENANG, Malaysia–(BUSINESS WIRE)–Motorola
Solutions
 is celebrating 45 years of innovation in Malaysia,
recognising the country’s highly skilled engineering talent and
capability to deliver advanced technologies for customers all over the
world.

Motorola Solutions first established supply chain operations in Penang,
Malaysia in 1974. Today, it develops technologies across its
mission-critical technology ecosystem at the facility.

In 2014 the company opened its ‘Innoplex’ research and development (R&D)
centre in Penang, its largest R&D centre outside of North America.
Equipped with state-of-the-art laboratories and product design and
development capabilities, the centre develops next generation Land
Mobile Radio (LMR), broadband-LTE devices and system solutions for
Motorola Solutions’ customers worldwide.

Leading-edge solutions and services designed and developed in Penang
have been deployed by public safety agencies across the world. This
includes the trusted APX
8000HXE HazLoc radio
 used by fire and rescue teams working in the
presence of chemicals and gases and the WAVE
TLK100 Two-Way Radio
 that enables coverage on nationwide cellular
networks with the ease of two-way radio communication and functionality.

The Innoplex continues to deliver a variety of innovative services
including 24/7 network monitoring, management and guaranteed reliability
for Motorola Solutions’ mission-critical customers.

Malaysia prominent within expanding Asia Pacific talent base

Motorola Solutions’ thriving operations in Malaysia have enabled it to
expand its Penang workforce from 10 software engineers to a team of more
than 1,700 today. These highly-skilled roles include industrial design,
software, electrical, electronics and mechanical engineering.

Penang’s expert teams conduct rigorous compliance testing to meet and
exceed product standards all over the world while continuing the
development of new solutions in partnership with customers.

Motorola Solutions’ rapidly growing software engineering workforce in
Asia Pacific is now approaching 2,000. This includes 160 video analytics
and AI specialists in Vietnam added through the recent acquisition of VaaS and
60 mobile applications developers with Gridstone in
Australia.

Motorola Solutions continues to evolve its mission-critical ecosystem
of technologies across voice, video security, software and managed
services. Our highly skilled teams in Malaysia play a significant role
in developing these technologies and accelerating their adoption all
over the world,” said John Andersen, deputy managing director of the
Motorola Solutions Penang Operations and Design Centre.

We are proud to have extended our journey to 45 years and look forward
to continuing to take Malaysian innovation to the world,” he said.

Through its charitable arm, the Motorola Solutions Foundation, the
company has provided more than USD $700,000 to support Malaysian
initiatives to advance education and research within STEM-related
fields. This includes the Penang Science Cluster which educates more
than 3,000 students and 300 teachers from 75 schools on design thinking
process, coding and electronics.

About Motorola Solutions

Motorola Solutions is a global leader in mission-critical
communications. Our technology platforms in communications, command
centre software, video security solutions and managed and support
services make cities safer and help communities and businesses thrive.
At Motorola Solutions, we are ushering in a new era in public safety and
security. Learn more at www.motorolasolutions.com.

MOTOROLA, MOTOROLA SOLUTIONS and the Stylized M Logo are trademarks
or registered trademarks of Motorola Trademark Holdings, LLC and are
used under license. All other trademarks are the property of their
respective owners. ©2019 Motorola Solutions, Inc. All rights reserved.

Contacts

Damien Batey
Motorola Solutions
Mobile: +61 (0) 428 036 806
Damien.Batey@motorolasolutions.com

Michael Lee
Motorola Solutions
Mobile: +65 9755 7025
MichaelKitWai.Lee@motorolasolutions.com

Continue Reading

Business Wire

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ra Medical Systems, Inc.

Business Wire

Published

on

Reading Time: 2 minutes

BENSALEM, Pa.–(BUSINESS WIRE)–$RMED #classaction–Law Offices of Howard G. Smith reminds investors of the upcoming August
9, 2019 
deadline to file a lead plaintiff motion in the class
action filed on behalf of investors who purchased Ra Medical Systems,
Inc. (“Ra Medical” or the “Company”) (NYSE: RMED)
securities pursuant and/or traceable to the registration statement and
prospectus (collectively, the “Registration Statement”) issued in
connection with the Company’s September 2018 initial public offering
(“IPO” or the “Offering”).

Investors suffering losses on their Ra Medical investments are
encouraged to contact the Law Offices of Howard G. Smith to discuss
their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

In September 2018, Ra Medical completed its initial public offering
(“IPO”), issuing approximately 4.5 million shares of common stock priced
at $17 per share. On March 14, 2019, the Company revealed that its
fourth quarter 2018 financial results had been negatively impacted by
issues related to the hiring and training of qualified sales personnel
and certain production limitations.

On this news, the Company’s share price fell $2.14 per share, nearly
33%, to close at $4.43 per share on March 15, 2019, thereby injuring
investors. Since the IPO, Ra Medical’s stock has traded as low as $3.40
per share, significantly below the $17 offering price.

The complaint filed in this class action alleges that throughout the
Class Period, Defendants made materially false and/or misleading
statements, as well as failed to disclose material adverse facts about
the Company’s business, operations, and prospects. Specifically,
Defendants failed to disclose to investors: (1) that the Company’s
evaluation of sales personnel candidates was inadequate; (2) that the
Company’s training program for sales personnel was inadequate; (3) that,
as a result, the Company could not reasonably assure that its newly
hired sales personnel were adequately experienced; (4) that, as a
result, the Company would suffer a shortage of qualified sales
personnel; (5) that the Company’s manufacturing process could not
reasonably support increased catheter production; (6) that, as a result,
the Company would suffer production delays; and (7) that, as a result of
the foregoing, Defendants’ positive statements about the Company’s
business, operations, and prospects were materially misleading and/or
lacked a reasonable basis.

If you purchased shares of Ra Medical during the Class Period you may
move the Court no later than August 9, 2019 to ask the
Court to appoint you as lead plaintiff if you meet certain legal
requirements. To be a member of the class action you need not take any
action at this time; you may retain counsel of your choice or take no
action and remain an absent member of the class action. If you wish
to learn more about this class action, or if you have any questions
concerning this announcement or your rights or interests with respect to
these matters, please contact Howard G. Smith, Esquire, of Law Offices
of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania
19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by
email to howardsmith@howardsmithlaw.com,
or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Continue Reading

Font Resizer

Subscribe to PICANTE via Email

Enter your email address to subscribe to PICANTE and receive notifications of new posts by email.

Follow us on Facebook

Read more from our authors

Follow our Tweets

Trending

Please turn AdBlock off